CIBC Private Wealth Group
ABUS icon

CIBC Private Wealth Group’s Arbutus Biopharma ABUS Stock Holding History

CIBC Private Wealth Group’s Portfolio ABUS Stock Details ABUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,450
Closed -$18.3K – 3082
2024
Q4 		$18.3K Hold
5,450
– – ﹤0.01% 2090
2024
Q3 		$21K Hold
5,450
– – ﹤0.01% 2134
2024
Q2 		$17.8K Hold
5,450
– – ﹤0.01% 2079
2024
Q1 		$14K Buy
+5,450
New +$14.1K ﹤0.01% 2157

Other funds holding ABUS

Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
FC
Foursixthree Capital New York $268M AUM 115.24% 1-Year Est. Return
BCP
BlackBarn Capital Partners New York $1.24B AUM 55.98% 1-Year Est. Return

CIBC Private Wealth Group's ABUS Position: Q1 2025 in Review

CIBC Private Wealth Group sold out of Arbutus Biopharma (ABUS) in Q1 2025, closing a stake of 5,450 shares — an estimated $18.3K sold.

CIBC Private Wealth Group first reported a position in ABUS in Q1 2024 and held it in 4 quarters. The position peaked at $21K in Q3 2024. 167 funds tracked by Wall St. Rank hold ABUS as of Q1 2025.

  • CIBC Private Wealth Group reported no remaining Arbutus Biopharma position as of Q1 2025 after selling out during the quarter.
  • CIBC Private Wealth Group sold 5,450 Arbutus Biopharma shares in Q1 2025, an estimated $18.3K.
  • CIBC Private Wealth Group first reported a position in Arbutus Biopharma in Q1 2024 and held it in 4 quarters.
  • CIBC Private Wealth Group's Arbutus Biopharma position peaked at $21K in Q3 2024.
  • 167 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q1 2025.

Based on CIBC Private Wealth Group's 13F filing for Q1 2025, filed 14 May 2025.